Acceleron and Shire Conclude Collaboration on ACE-031

  Acceleron and Shire Conclude Collaboration on ACE-031

    Acceleron continues development of three phase 2 drugs in oncology and
                                  hematology

Business Wire

CAMBRIDGE, Mass. -- May 2, 2013

Acceleron Pharma, Inc., a biopharmaceutical company developing protein
therapeutics for cancer and orphan diseases, today reported that Shire plc
(LSE: SHP, NASDAQ: SHPG) has concluded the collaboration with Acceleron on
ACE-031 and related molecules. The clinical development of ACE-031 was
suspended in February 2011 and since then the companies have conducted
preclinical studies to determine whether to resume clinical studies. The
companies have now decided not to restart the development of this program.
Acceleron remains focused on the eleven phase 2 clinical studies currently
underway across its three investigational protein therapeutics - sotatercept,
dalantercept and ACE-536.

“While we are disappointed in the outcome of the ACE-031 program, the research
provided valuable insights that can be applied across Acceleron’s pipeline of
novel compounds and may benefit other patients in the future. In the last six
months, we have initiated seven of the eleven ongoing phase 2 trials and we
are committed to achieving our goal of beginning at least one phase 3 study in
2014,” said John Knopf, Ph.D., Chief Executive Officer, Acceleron. “Shire has
been an excellent collaborator and we thank them, our clinical investigators
and the patient community for their contributions to the ACE-031 program.”

About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover,
develop, manufacture and commercialize novel protein therapeutics for orphan
diseases and cancer. Acceleron’s scientific approach takes advantage of its
unique insight to discover first-in-class therapies based on the TGF-β protein
superfamily. Acceleron utilizes proven biotherapeutic technologies and
capitalizes on the company’s internal GMP manufacturing capability to advance
its therapeutic programs rapidly and efficiently. The investors in Acceleron
include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer
Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors,
Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further
information on Acceleron, please visit www.acceleronpharma.com.

Contact:

Acceleron Pharma:
Steven Ertel, 617-649-9234
Chief Business Officer
or
Suda Communications LLC
Media
Maureen L. Suda, 585-387-9248
 
Press spacebar to pause and continue. Press esc to stop.